Picard Medical, Inc. (PMI) Stock Price & Analysis
Picard Medical, Inc. (PMI) rose 21.07% to USD 0.32 as of June 10, 2026 at 02:36 UTC, according to Nexqual real-time market data.
PMI last closed at USD 0.26; the session ranged USD 0.23–0.36 on volume of 36,230,215 shares. Market capitalization is $29.88M, with a 52-week range of USD 0.11–13.68 (ASE). Source: Nexqual, June 10, 2026 at 02:36 UTC.
Key Statistics (as of June 10, 2026 at 02:36 UTC)
| Price | USD 0.32 |
|---|---|
| Change | ▲ 21.07% (up) |
| Previous Close | USD 0.26 |
| Open | USD 0.22 |
| Day Range | USD 0.23 – 0.36 |
| 52-Week Range | USD 0.11 – 13.68 |
| Volume | 36,230,215 shares |
| Market Cap | $29.88M |
| Exchange | ASE |
Technical Analysis (PMI)
Nexqual's technical model rates PMI "SELL" based on 2 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 02:36 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 43.94 (neutral) |
| vs SMA50 | Below (USD 0.52) |
| MACD | -0.05 (negative) |
Analyst Ratings (PMI)
Wall Street analysts rate PMI "Hold", per Nexqual as of June 10, 2026 at 02:36 UTC.
| Consensus Rating | Hold |
|---|---|
| Buy / Hold / Sell | 0 / 1 / 0 |
Earnings (PMI)
| Next Earnings Date | 2026-08-14 |
|---|---|
| EPS Estimate | USD -0.03 |
| Revenue Estimate | $1.55M |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Financials & Fundamentals (PMI)
| Total Revenue | $5.47M |
|---|---|
| Revenue Growth (YoY) | +85.50% |
| Gross Margin | +7.84% |
| Operating Margin | -392.26% |
| Profit Margin | +0.00% |
| Current Ratio | 0.75 |
| Total Cash | $121,000 |
| Total Debt | $3.27M |
| Free Cash Flow | $-15.29M |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Financial Health Score (PMI)
Nexqual rates Picard Medical, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:36 UTC.
| Growth | Strong — Revenue +86% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $121K cash vs $3M debt |
| Cash Flow | Weak — Operating cash flow -$17M |
| Efficiency | Mixed — No data |
Ownership (PMI)
| Insider Ownership | +61.61% |
|---|---|
| Institutional Ownership | +8.01% |
| Shares Outstanding | 93.35M |
| Float | 39.51M |
| Short % of Float | +2.94% |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Leadership (PMI)
Picard Medical, Inc. is led by Patrick N. J. Schnegelsberg (age 61), CEO & Director, per Nexqual as of June 10, 2026 at 02:36 UTC.
| CEO & Director | Patrick N. J. Schnegelsberg (age 61) |
|---|---|
| Chief Operating Officer | Matthew Schuster (age 44) |
| Chief Technology Officer of SynCardia Systems, LLC | Frank Tinker (age 69) |
From Picard Medical, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Picard Medical, Inc., together with its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products.
- The company offers SynCardia TAH, an artificial heart for patients that is designed to function as a failed human heart in patients suffering from advanced heart failure.
- The company operates in the United States, Europe, and internationally.
- Picard Medical, Inc. operates as a subsidiary of Hunniwell Picard I, Llc.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RDN | Radian Group Inc. | USD 34.25 | ▲ 1.33% |
| MTG | MGIC Investment Corporation | USD 25.55 | ▲ 0.16% |
| MBI | MBIA Inc. | USD 6.08 | ▼ 0.82% |
| TGIC | TRIAD GUARANTY INC | USD 0 | ▲ 0% |
| PRE | Prenetics Global Limited | USD 20.93 | ▲ 5.39% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:36 UTC. This page is informational and not investment advice.